Genekor focuses on prognosis, prediction and diagnosis in molecular oncology by providing the highest quality services for individualized treatment.

Who we are


Our journey began in 2007 and we constantly grow in order to provide the highest quality services in the Molecular Medicine sector.

A passionate team sharing the same vision on quality healthcare and molecular science is working together in order to provide patients and physicians with reliable actionable information.

 

Our aim is to individualize the journey of patients from diagnosis to treatment selection and response and to reveal their genetic predisposition to Hereditary Syndromes.

Our mission is to revolutionize the personalized treatment of patients by developing and offering highly sensitive and specific molecular assays that are applicable in everyday clinical practice, incorporating state-of-the-art technology and assisting physicians in applying cutting edge tools for individualized medicine worldwide

The clinical expertise of Genekor focuses on:

  • Response to Targeted Therapy
  • Pharmacogenetics
  • Determination of Hereditary Cancer, cardiovascular Diseases and Neurological Disorders
  • New Unique Technological Platforms (OncotypeDX BreastTM, HerediGENETM, PrIMeTM, Cordis DXTM, Cerebrum DX TM, PCA3TM)

The specialized laboratories of GeneKor Medical S.A. are accredited by the Hellenic Accreditation Systems S.A (ESYD) under the terms of the ELOT EN ISO 15189:2012 (Cert. No. 822) and Certified with ISO 9001:2015 (Cert. No. 041150049) and ELOT ISO/IEC 27001:2013 (Cert.No 048190009) by TUV NORD HELLAS.

GeneKor is staffed by board certified internationally recognized and published scientists and doctors who are able to provide analysis and recommendations to physicians and their patients. Therefore, GeneKor is in position to carry out all existing molecular biology assays. GeneKor offers to the treating physicians of various specialties tools to individualize their patients’ treatment needs.

At GeneKor, we are devoted at offering services of the highest quality, by constantly monitoring the scientific developments in the health sector, updating our laboratory equipment and maximizing our levels of accuracy and reliability.

GeneKor is actively establishing its international presence with an ultimate goal to extend its collaborations in more countries. Our strategic goal is the constant incorporation of new technology platforms and assays in order to always provide the most up-to-date, reliable and cutting edge tools to the treating physicians.

Certifications

The Management and the Scientific Team of GeneKor Medical laboratories are focused on providing the highest quality of Molecular Services.

  • The specialized laboratories of GeneKor Medical S.A.  are accredited by the Hellenic Accreditation Systems S.A (ESYD) under the terms of the ELOT EN ISO 15189:2012 (Cert. No. 822).
  • Certified with ELOT EN ISO 9001:2015 (Cert. No. 041150049) and ELOT ISO/IEC 27001:2013 (Cert.No 048190009) by TUV NORD HELLAS.
  • Our services are assured by participating in proficiency testing (PT) programs by:
    • CAP (College of American Pathologists).
    • External Quality Assurance EMQN (European Molecular and Genetics Quality Network).
    • UKNEQAS –ICC & ISH (United Kingdom National External Quality Assessment Services, Immunohistochemistry & In-situ Hybridization).
    • GenQA (Genomics Quality Assessment).

Genekor is certified by external quality assessment for the following tests:

  • Mutation analysis in BRCA1 & BRCA2 genes (Breast Cancer susceptibility genes 1 and 2) – EMQN & CAP
  • Somatic mutation analysis (EGFR, BRAF, KRAS, KIT, NRAS, HRAS & PDGFRA gene) – CAP, EMQN & GenQA
  • Analysis of DNA Microsatellite Instability (MSI) - GenQA
  • Detection and quantification of the ALK gene rearrangements – UKNEQAS (ICC&ISH)
  • Detection and quantification of the overexpression of the HER2/neu gene - UKNEQAS (ICC&ISH)

Certifications Files

Please click on the Download button, in order to view the certifications of Genekor Medical S.A.

 

Download

General Meeting

  • Invitation of the Shareholders of the Company under the title “GENEKOR PRIVATE DIAGNOSTIC LABORATORY MEDICAL SA” and the distinctive title GENEKOR IAE in the annual Regular General Meeting on the 14th of June  2018, Tuesday, at 16.00 p.m. at the Company's premises in Gerakas, Pallini, Attica (52 Spaton Ave). 

  • Invitation of the Shareholders of the Company under the title “GENEKOR PRIVATE DIAGNOSTIC LABORATORY MEDICAL SA” and the distinctive title GENEKOR IAE in the annual Regular General Meeting on the 10th of September  2020, Tuesday, at 16.00 p.m. at the Company's premises in Gerakas, Pallini, Attica (52 Spaton Ave). 

Physician's References

Mircea GONGU, MD Position: Chief of works, Oncology department, MEDEUROPA Bucharest

“Genekor’s reliability and consistency are the reasons I have been collaborating with this company for more than 9 years. I trust the results, because of the technology and the confirmation techniques they use reassure me of their validity. Also, the scientific consultants are constantly available for help during the test procedure, but also after the results, in order to help with any interpretation needed.”

;

Dr. Christos J.Markopoulos Professor of Surgery – Athens University Medical School President: UEMS – EBS - Division of Breast Surgery

"I have been working with Genekor for over 15 years. I fully trust them because they use very up-to-date technologies and methods, that make the results I receive truly reliable. One of Genekor’s advantages is the detailed and explicit reports and the ongoing scientific support that are very helpful and much appreciated. Everyday collaboration in the process of samples and the web based immediate information of the results is also worth mentioning. Last but not least, they are always willing to support related research, training and educational projects."

;

Dr. Vassilios Venizelos Specialty: Breast Surgeon - Mastology Specialist Position: Head of Breast Unit METROPOLITAN Hospital Director of Breast Surgery Clinic METROPOLITAN Hospital President of the Hellenic Breast Surgery Society

"Genekor Medical S.A. has proven to be a valuable partner. They have a deep knowledge and experience in molecular medicine for cancer, as well as an understanding for the physician’s needs and demands. They provide prompt, thorough and reliable results. "

;

Dr. Paris Kosmidis Position: Head of B. Pathology-Oncology Unit at Hygeia Hospital Director of Scientific Board at Hygeia Hospital

"Genekor Medical S.A. is the company I trust when I deal with patients with complicated cancer cases. The procedures and the reports are very professional and thorough, but also straightforward and quick. They show a genuine interest for the patient and the physician they work with. "

;

Athena Christopoulou, MD,PhD Position: Head of Pathology-Oncology Unit at St. Andreas Hospital of Patras

“Genekor’s experience in cancer molecular testing and reporting has made the implementation of precision medicine in the everyday clinical practice easier and more consistent. I definitely recommend Genekor Medical for the genetic testing required, especially when dealing with aggressive and rare cancers.”

;

Gabriel Cristian VIISOREANU, MD Position: Chief of works, Oncology Surgeon, Private Breast Institute MONZA

“Genekor always delivers thorough and articulate reports. Also, they work closely with the physician in every step of the patient’s testing process and after the report has been distributed.”

;
Change cookies consent Revoke cookies consent